Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dirucotide in Secondary Progressive Multiple Sclerosis
NCT00869726Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2004
- Primary completion
- May 2009
- Modality
- Peptides
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in secondary-progressive multiple sclerosis (SPMS) comparing Dirucotide with Placebo (2 arms). Primary endpoint: Time to worsening of disability by Kurtzke Expended Disability Status (EDSS) at 24 months. Started Dec 2004; status: completed.
02
Drugs
dirucotide
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NCT00869726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00869726.